Article thumbnail

Screening for left ventricular hypertrophy in patients with type 2 diabetes mellitus in the community

By Jithendra B Somaratne, Gillian A Whalley, Katrina K Poppe, Mariska M ter Bals, Gina Wadams, Ann Pearl, Warwick Bagg and Rob N Doughty
Topics: Original Investigation
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2003). A: Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart.
  2. (2010). A: Left ventricular dysfunction screening in hypertensive patients with N-terminal pro-B-type natriuretic peptide and electrocardiogram.
  3. (2005). AD: The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus. Diabetologia
  4. (2002). Adult Treatment Panel III: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation
  5. American Diabetes Association: Standards of Medical Care in Diabetes -
  6. (2010). Brain natriuretic peptide is related to diastolic dysfunction whereas urinary albumin excretion rate is related to left ventricular mass in asymptomatic type 2 diabetes patients. Cardiovascular Diabetology
  7. (1990). Castelli WP: Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation
  8. (2004). Dahlöf B: Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA
  9. (2010). DM: Hemodynamic Determinants of Myocardial B-Type Natriuretic Peptide Release: Relative Contributions of Systolic and Diastolic Wall Stress. Hypertension
  10. (2010). Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides. Cardiovascular Diabetology
  11. (1970). Electrocardiographic Left Ventricular Hypertrophy and Risk of Coronary Heart Disease. Annals of Internal Medicine
  12. (2006). et al: Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation
  13. (2003). et al: Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial.
  14. (2004). How much echo left ventricular hypertrophy would be missed in diabetics by applying the Losartan Intervention For Endpoint Reduction electrocardiogram criteria to select patients for angiotensin receptor blockade?
  15. (1993). Improved detection of echocardiographic left ventricular hypertrophy using a new electrocardiographic algorithm.
  16. (2008). LM: Prevalence and predictors of cardiac hypertrophy and dysfunction in patients with Type 2 diabetes. Clinical Science
  17. (1985). MC: Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria.
  18. (2004). N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris.
  19. (2004). PC: Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in Type 2 diabetes: The Casale Monferrato Study. Diabetic Medicine
  20. (2003). Porcellati C: Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis.
  21. (2003). RW: Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial.
  22. (1998). Selection bias in clinical research when subjects are excluded because of failure to estimate left ventricular mass by echocardiography.
  23. (2003). Strong Heart S: Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the Strong Heart Study. Diabetes Care
  24. (2004). TH: Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocrine Reviews
  25. (2005). TH: Screening for heart disease in diabetic subjects.
  26. (2007). The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC):
  27. (1949). TP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads.
  28. (2007). Vasan RS: Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals. Circulation